170 related articles for article (PubMed ID: 35585821)
21. The Anticancer Effects of Marine Carotenoid Fucoxanthin through Phosphatidylinositol 3-Kinase (PI3K)-AKT Signaling on Triple-Negative Breast Cancer Cells.
Ahmed SA; Mendonca P; Messeha SS; Oriaku ET; Soliman KFA
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202644
[TBL] [Abstract][Full Text] [Related]
22. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells.
Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y
Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
[TBL] [Abstract][Full Text] [Related]
24. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
25. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.
Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J
Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982
[TBL] [Abstract][Full Text] [Related]
26. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway.
Zhang LY; Shen ZX; Guo L
Cancer Invest; 2022 Apr; 40(4):313-324. PubMed ID: 35040385
[TBL] [Abstract][Full Text] [Related]
29. NDC80 Enhances Cisplatin-resistance in Triple-negative Breast Cancer.
Li J; Xu X; Peng X
Arch Med Res; 2022 Jun; 53(4):378-387. PubMed ID: 35346500
[TBL] [Abstract][Full Text] [Related]
30. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
32. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
Choi C; Kwon J; Lim S; Helfman DM
Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
[TBL] [Abstract][Full Text] [Related]
33. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
34. Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
Yellapu NK; Ly T; Sardiu ME; Pei D; Welch DR; Thompson JA; Koestler DC
BMC Cancer; 2022 Jun; 22(1):627. PubMed ID: 35672711
[TBL] [Abstract][Full Text] [Related]
35. Effecacy of Biejia (Carapax Trionycis) and Ezhu (Rhizoma Curcumae Phaeocaulis) couplet medicine on epithelial-mesenchymal transition, invasion and migration of MDA-MB-231 triple negative breast cancer cells via PI3K/Akt/mTOR signaling pathway.
Zhu MJ; Xie S; Xie Q; Zhu JL; Huang YZ
J Tradit Chin Med; 2021 Dec; 41(6):853-861. PubMed ID: 34939381
[TBL] [Abstract][Full Text] [Related]
36. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
[TBL] [Abstract][Full Text] [Related]
37. Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.
Xiao YS; Zeng D; Liang YK; Wu Y; Li MF; Qi YZ; Wei XL; Huang WH; Chen M; Zhang GJ
Cancer Lett; 2019 Jan; 440-441():156-167. PubMed ID: 30336197
[TBL] [Abstract][Full Text] [Related]
38. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
Cheng W; Liu D; Guo M; Li H; Wang Q
Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
[TBL] [Abstract][Full Text] [Related]
39. MiR-193 promotes cell proliferation and invasion by ING5/PI3K/AKT pathway of triple-negative breast cancer.
Xu JH; Zhao JX; Jiang MY; Yang LP; Sun ML; Wang HW
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3122-3129. PubMed ID: 32271430
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]